Hyderabad: Glenmark Pharmaceuticals Ltd on Wednesday launched Digihaler, India’s first digital dose inhaler for asthma and chronic obstructive pulmonary disease (COPD) patients. The product costs 300-450, depending on the strength and the combination of drugs in the inhaler.
Glenmark said it has already launched two combination drugs that will go in with the inhaler. “This inhaler provides accurate digital dose counter along with low dose warning indicator to enable asthma and chronic patients to track adherence to their therapy,” Glenmark said.
“We are planning to launch more drugs to support Digihaler in coming months,” said Sujesh Vasudevan, president and head of India formulations and Africa region at Glenmark.
Vasudevan said Glenmark wants to be among top three of 500 crore worth inhaler market, dominated by Cipla Ltd, followed by Lupin Ltd and Glaxosmithkline Pharmaceuticals Ltd.
